# OnCo record pd1-checkpoint (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/pd1-checkpoint/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "pd1-checkpoint" ;
  schema:name "PD-1 / PD-L1 immune checkpoint & T-cell activation"@en ;
  schema:description "How T cells decide to attack. A T cell needs to see the target (TCR-MHC) and get a 'go' signal (CD28). PD-1 and CTLA-4 are 'stop' signals; tumours exploit them. Checkpoint inhibitors remove the stop."@en ;
  schema:url <https://onco.cc/pathways/pd1-checkpoint/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Immune_checkpoint> ;
  owl:sameAs <http://www.wikidata.org/entity/Q21686041> ;
  schema:citation <https://en.wikipedia.org/wiki/Immune_checkpoint>, <https://doi.org/10.1182/blood-2010-05-282780>, <https://doi.org/10.1200/JCO.2016.66.4482> ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/neoantigen-mrna-vaccine/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/lag3/>, <https://onco.cc/targets/tigit/>, <https://onco.cc/targets/cd3/>, <https://onco.cc/targets/cd80/>, <https://onco.cc/targets/cd28/>, <https://onco.cc/targets/b7h4/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/relatlimab-nivolumab/>, <https://onco.cc/drugs/ivonescimab/> .